Loading...
Loading...
GERN| Name | Value |
|---|---|
| Revenues | 39.6M |
| Cost of Revenue | 1.2M |
| Gross Profit | 38.4M |
| Operating Expense | 55.1M |
| Operating I/L | -16.7M |
| Other Income/Expense | -3.1M |
| Interest Income | 5.2M |
| Pretax | -19.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -19.8M |
Geron Corporation is a late-stage clinical biopharmaceutical company specializing in the development and commercialization of therapeutics for myeloid hematologic malignancies. Its primary focus is on the development of imetelstat, a telomerase inhibitor currently in Phase 3 clinical trials. Imetelstat is designed to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies, targeting low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
